Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Trial Start • Phase 2Trial initiation Mon, Jun 29, 2026, 7:25 AM EDT
Company profile
Tonix Pharmaceuticals Holding Corp.
Pipeline7 assets
Latest news21 items
All newsTonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
Presentation / Abstract • Phase 1